Dao Kim-Hien T
Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Mail Code: UHN73C, 3181 South West Sam Jackson Park Road, Portland, OR 97239, USA.
Med Clin North Am. 2017 Mar;101(2):333-350. doi: 10.1016/j.mcna.2016.09.006.
Myelodysplastic syndrome (MDS) is a heterogeneous, clonal stem cell disorder of the blood and marrow typically diagnosed based on the presence of persistent cytopenia(s), dysplastic cells, and genetic markers. Common issues that arise in the clinical management include difficulty confirming MDS diagnosis, lack of a standard approach with novel agents in MDS, and few prospective long-term, randomized controlled MDS clinical studies to guide allogeneic blood and marrow transplant. With the recent genetic characterization of MDS, certain aspects of these issues will be better addressed by integrating genetic data into clinical study design and clinical practice.
骨髓增生异常综合征（MDS）是一种血液和骨髓的异质性克隆性干细胞疾病，通常根据持续性血细胞减少、发育异常细胞和基因标志物的存在来诊断。临床管理中出现的常见问题包括难以确诊MDS、缺乏针对MDS新型药物的标准治疗方法，以及几乎没有前瞻性长期随机对照MDS临床研究来指导异基因造血干细胞移植。随着最近对MDS的基因特征分析，通过将基因数据整合到临床研究设计和临床实践中，这些问题的某些方面将得到更好的解决。
